0001193125-26-219371
SEC filingSavara's Q1 2026 net loss widened to $37.3M as operating expenses rose, driven by higher personnel costs and stock-based compensation, ahead of the November 2026 PDUFA date for MOLBREEVI.
Savara's operating loss for Q1 2026 was $39.0 million, compared to $28.4 million in Q1 2025, a 37% increase. The net loss was $37.3 million, or $(0.15) per diluted share, versus $26.6 million, or $(0.12) per diluted share, in the prior year. The increase in operating expenses was primarily attributable to higher personnel costs, including increased stock-based compensation, and other departmental overhead, partially offset by a decrease in certain commercial activities. As the company progresses toward the November 22, 2026 PDUFA date for MOLBREEVI, expenses are expected to continue rising due to ongoing development, manufacturing, and regulatory activities.
The FDA extended the review of the MOLBREEVI Biologics License Application to November 22, 2026. Savara's future success depends on obtaining regulatory approval and commercializing MOLBREEVI. The company will continue to need additional capital to support its operations, and there is no guarantee of approval or commercial success.